{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-25-000030","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.452802+00:00","generated_at":"2026-05-17T00:40:40.841375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics Q3 net loss $16.4M, cash $65.7M; key trial updates due Q4 2025","bullets":["Cash and equivalents $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026.","Net loss of $16.4M for Q3 2025, comparable to $16.7M in Q3 2024; R&D expense $11.6M, G&A $4.1M.","WTX-124 received Fast Track Designation; interim Phase 1/1b data and End of Phase 1 FDA meeting expected in Q4 2025.","WTX-330 Phase 1b/2 update and development plan expected in Q4 2025.","WTX-1011 (anti-STEAP1 T-cell engager) in IND-enabling studies; target candidate nomination planned by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-25-000030","json":"https://secwatch.observer/filing/0001785530-25-000030.json","markdown":"https://secwatch.observer/filing/0001785530-25-000030.md","text":"https://secwatch.observer/filing/0001785530-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000030/0001785530-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000030/howl-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:40:40.841375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}